Surgical treatment of giant pituitary adenomas

Strategies and results in a series of 95 consecutive patients

Pietro Mortini, Raffaella Barzaghi, Marco Losa, Nicola Boari, Massimo Giovanelli

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge. We report our experience in a large, consecutive series of patients with giant adenomas. METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department. Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%). The mean age at the time of surgery (±standard error of the mean) was 48.4 ± 1.5 years; there were 66 men (69.5%) and 29 women (20.5%). RESULTS: In total, 111 surgical procedures were performed. Of these, 85 approaches (76.6%) were transsphenoidal and 26 (23.4%) were transcranial. Visual improvement occurred in 59 of the 79 patients with preoperative defect who could be evaluated after surgery (74.7%). Radical tumor excision was obtained in 14 patients (14.7%). Adjuvant medical and radiation therapies led to 74.5% (95% confidence interval, 62.7-86.4%) control of tumor growth at 5 years. This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors. In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P <0.01). CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.

Original languageEnglish
Pages (from-to)993-1002
Number of pages10
JournalNeurosurgery
Volume60
Issue number6
DOIs
Publication statusPublished - Jun 2007

Fingerprint

Pituitary Neoplasms
Adenoma
Radiotherapy
Neoplasms
Therapeutics
Hormones
Growth
Tumor Burden
Confidence Intervals

Keywords

  • Pituitary giant adenomas
  • Radiotherapy
  • Transcranial pituitary surgery
  • Transsphenoidal surgery

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Surgical treatment of giant pituitary adenomas : Strategies and results in a series of 95 consecutive patients. / Mortini, Pietro; Barzaghi, Raffaella; Losa, Marco; Boari, Nicola; Giovanelli, Massimo.

In: Neurosurgery, Vol. 60, No. 6, 06.2007, p. 993-1002.

Research output: Contribution to journalArticle

Mortini, Pietro ; Barzaghi, Raffaella ; Losa, Marco ; Boari, Nicola ; Giovanelli, Massimo. / Surgical treatment of giant pituitary adenomas : Strategies and results in a series of 95 consecutive patients. In: Neurosurgery. 2007 ; Vol. 60, No. 6. pp. 993-1002.
@article{8bd98ee6f24543e1b9cd53bb72be78fd,
title = "Surgical treatment of giant pituitary adenomas: Strategies and results in a series of 95 consecutive patients",
abstract = "OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge. We report our experience in a large, consecutive series of patients with giant adenomas. METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department. Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7{\%}), whereas hormone-secreting adenomas numbered only 25 (26.3{\%}). The mean age at the time of surgery (±standard error of the mean) was 48.4 ± 1.5 years; there were 66 men (69.5{\%}) and 29 women (20.5{\%}). RESULTS: In total, 111 surgical procedures were performed. Of these, 85 approaches (76.6{\%}) were transsphenoidal and 26 (23.4{\%}) were transcranial. Visual improvement occurred in 59 of the 79 patients with preoperative defect who could be evaluated after surgery (74.7{\%}). Radical tumor excision was obtained in 14 patients (14.7{\%}). Adjuvant medical and radiation therapies led to 74.5{\%} (95{\%} confidence interval, 62.7-86.4{\%}) control of tumor growth at 5 years. This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors. In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P <0.01). CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.",
keywords = "Pituitary giant adenomas, Radiotherapy, Transcranial pituitary surgery, Transsphenoidal surgery",
author = "Pietro Mortini and Raffaella Barzaghi and Marco Losa and Nicola Boari and Massimo Giovanelli",
year = "2007",
month = "6",
doi = "10.1227/01.NEU.0000255459.14764.BA",
language = "English",
volume = "60",
pages = "993--1002",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Surgical treatment of giant pituitary adenomas

T2 - Strategies and results in a series of 95 consecutive patients

AU - Mortini, Pietro

AU - Barzaghi, Raffaella

AU - Losa, Marco

AU - Boari, Nicola

AU - Giovanelli, Massimo

PY - 2007/6

Y1 - 2007/6

N2 - OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge. We report our experience in a large, consecutive series of patients with giant adenomas. METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department. Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%). The mean age at the time of surgery (±standard error of the mean) was 48.4 ± 1.5 years; there were 66 men (69.5%) and 29 women (20.5%). RESULTS: In total, 111 surgical procedures were performed. Of these, 85 approaches (76.6%) were transsphenoidal and 26 (23.4%) were transcranial. Visual improvement occurred in 59 of the 79 patients with preoperative defect who could be evaluated after surgery (74.7%). Radical tumor excision was obtained in 14 patients (14.7%). Adjuvant medical and radiation therapies led to 74.5% (95% confidence interval, 62.7-86.4%) control of tumor growth at 5 years. This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors. In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P <0.01). CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.

AB - OBJECTIVE: Giant pituitary adenomas, defined as those measuring at least 4 cm in maximum diameter, are a therapeutic challenge. We report our experience in a large, consecutive series of patients with giant adenomas. METHODS: Between 1990 and 2004, 95 patients with a giant pituitary adenomas underwent surgery at our department. Nonfunctioning pituitary adenoma was the most frequent type (n = 70; 73.7%), whereas hormone-secreting adenomas numbered only 25 (26.3%). The mean age at the time of surgery (±standard error of the mean) was 48.4 ± 1.5 years; there were 66 men (69.5%) and 29 women (20.5%). RESULTS: In total, 111 surgical procedures were performed. Of these, 85 approaches (76.6%) were transsphenoidal and 26 (23.4%) were transcranial. Visual improvement occurred in 59 of the 79 patients with preoperative defect who could be evaluated after surgery (74.7%). Radical tumor excision was obtained in 14 patients (14.7%). Adjuvant medical and radiation therapies led to 74.5% (95% confidence interval, 62.7-86.4%) control of tumor growth at 5 years. This was not different in patients with nonfunctioning pituitary adenomas compared with patients with hormone-secreting tumors. In the subgroup of patients with nonfunctioning pituitary adenomas, radiation therapy had a protective role against tumor growth (P <0.01). CONCLUSION: Maximal surgical removal of giant adenomas through the transsphenoidal or transcranial approach, or both, aimed to relieve compression of the optic pathway and reduce tumor volume as much as possible, offers the best chances to control the tumor when followed with adjuvant medical and radiation therapies.

KW - Pituitary giant adenomas

KW - Radiotherapy

KW - Transcranial pituitary surgery

KW - Transsphenoidal surgery

UR - http://www.scopus.com/inward/record.url?scp=34249826609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249826609&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000255459.14764.BA

DO - 10.1227/01.NEU.0000255459.14764.BA

M3 - Article

VL - 60

SP - 993

EP - 1002

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 6

ER -